Orpheus Medical Center OOD
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Nutritional and Metabolic Diseases
At Orpheus Medical Center OOD in Stara Zagora, clinical research is centered on cardiovascular disease prevention and lipid-related risk reduction. The studies focus on people with established atherosclerotic cardiovascular disease, elevated lipoprotein(a), or a high risk of future heart and vascular events.
- Testing new approaches to lower the chance of major cardiovascular events such as heart attack and stroke
- Evaluating treatments for people with ASCVD and elevated LDL cholesterol or lipoprotein(a)
- Comparing therapies aimed at improving prevention in adults at high cardiovascular risk
These trials are designed to help determine whether newer lipid-lowering therapies can better protect patients from serious outcomes than placebo and standard care.
Atherosclerotic Cardiovascular Risk Research
This site is also involved in studies of adults with high cardiovascular risk who have not previously had a myocardial infarction or stroke. The research aims to understand whether additional treatment can reduce the likelihood of first major events in patients already receiving optimized lipid management.
- Assessing prevention strategies for coronary heart disease death, myocardial infarction, and ischemic stroke
- Studying the impact of therapies added to existing lipid-lowering treatment
- Improving long-term protection for patients with elevated risk but no prior major event
The main goal is to evaluate treatment effectiveness in lowering the risk of serious cardiovascular outcomes before they occur.
Lipoprotein(a) and Advanced Prevention Studies
Research at Orpheus Medical Center OOD includes trials for patients with ASCVD and elevated lipoprotein(a), a factor linked to increased cardiovascular risk. These studies are exploring whether targeted therapy can improve prevention beyond standard cholesterol control.
- Examining whether lowering lipoprotein(a) can reduce coronary heart disease death and myocardial infarction
- Looking at the need for urgent coronary revascularization in people with established vascular disease
- Supporting development of more precise cardiovascular risk reduction strategies
Overall, the work is focused on testing whether new preventive treatments can better protect patients with difficult-to-treat atherosclerotic disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Orpheus Medical Center OOD
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study | Amgen Inc. | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atorvastatin | 1 | Unknown | 2021-11-26 | 2021-11-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.